期刊
NEURON
卷 74, 期 6, 页码 964-966出版社
CELL PRESS
DOI: 10.1016/j.neuron.2012.06.001
关键词
-
资金
- NINDS NIH HHS [R01 NS074312, R01 NS049501] Funding Source: Medline
Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's disease. In this issue of Neuron, Kordasiewicz et al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据